in partnership between
TMIC and the Metabolomics Society
Issue 32 - April 2014
Metabolomics Society News
All accepted abstracts by this deadline will be put on the official booklet. After this deadline, we will still accept late-breaking posters. These posters will be put in a room different from the exhibition area and their abstracts will NOT be included in the booklet, but only as a handout.
• Early Registration Deadline: April 10th 2014
Professor of Obstetrics at University College Cork, Consultant Obstetrician and Gynaecologist at Cork University Maternity Hospital, and Director of the newly funded Irish Centre for Fetal and Neonatal Translation Research (INFANT), Cork, Ireland
Louise Kenny (MB ChB (hons), PhD, MRCOG) is Professor of Obstetrics at University College Cork (UCC), a Consultant Obstetrician and Gynaecologist at Cork University Maternity Hospital and director of the newly funded Irish Centre for Fetal and Neonatal Translation Research (INFANT), Ireland’s first perinatal research centre. Louise has a longstanding clinical and research interest in uteroplacental insufficiency, adverse pregnancy outcome and pregnancy loss. Since her move to Ireland in 2006, Louise has raised over €18 million in external awarded peer reviewed grants and has developed a research group consisting of more than 40 researchers from a wide variety of clinical and scientific disciplines. In 2007, Louise was appointed as a Health Research Board Ireland Clinician Scientist. This 4 year award (of €1.6 million) underpinned the Screening for Pregnancy Endpoints (SCOPE) Study, a prospective longitudinal case cohort of pregnancy outcome which also forms part of one of the world’s most detailed global pregnancy biobanks (www.scopestudy.net).
In July 2009, Louise was awarded a Principal Investigator Programme grant from Science Foundation Ireland to continue her group’s pioneering new approach to biomarker development by focusing on metabolic changes in plasma. Using the SCOPE cohort, the Kenny group has discovered a consistent discriminatory metabolite signature in early pregnancy plasma preceding the onset of pre-eclampsia. This finding provides insight into disease pathogenesis, and offers the tantalizing promise of a robust presymptomatic screening test. Louise was awarded a Translational Award from the Wellcome Trust to develop these biomarkers into a clinically useful predictive test. This technology has recently been licensed to a campus based spin-out (www.metabolomicdiagnostics.com) and Louise has recently been awarded a €6 million grant under the auspices of the 7th Framework Programme for research to conduct a phase IIa clinical study of this test and platform (www.fp7-improved.eu).
In addition, together with her co-PIs in the Department of Paediatrics at UCC, Louise has established BASELINE (Babies After SCOPE, Evaluating Longitudinal Indices of Neurological and Nutritional Endpoints, www.baselinestudy.net). Funded by the Children’s Research Centre, the BASELINE study is the first longitudinal birth cohort study in Ireland and as such is a unique resource.
Louise’s work has resulted in >150 peer reviewed original papers, reviews and book chapters. She is the Editor of the 19th Edition of ‘Obstetrics by Ten Teachers’, the world’s leading undergraduate textbook in obstetrics and has received numerous awards including the William Blair Bell Lectureship from the Royal College of Obstetricians and Gynaecologists (RCOG) for contributions to original research in the field of women’s health. In addition, Louise is a reviewer for a wide range of international journals and research funding bodies and is a member of the RCOG Wellbeing of Women Scientific Advisory committee.
In this paper, the investigators used a metabolomics approach to distinguish between physically inactive overweight/obese women with metabolic syndrome (MetS) and metabolically healthy subjects. Using nuclear magnetic resonance spectroscopy to profile serum samples from fasting individuals, they sought to identify metabolic differences between 78 fat mass and body weight matched overweight/obese premenopausal women with and without MetS. To qualify as having MetS, individual patients had to meet three of the following five criteria: waist circumference >=88 cm, serum triacylglycerol >=1.7 mmol/L, and high density lipoprotein cholesterol (HDL-C) <1.30 mmol/L, blood pressure >= 130/85 mmHg and fasting glucose >=5.6 mmol/L. The researchers discovered three metabolites that were associated with all clinical risk factors: branched-chain amino acids and aromatic amino acids and orosomucoid. With additional work, these results could be used to develop a public health screening tool to identify individuals at cardio-metabolic risk.
There is a need for reliable biomarkers for early-stage detection of esophageal cancer (EC). In this study, the researchers analyzed serum samples from 25 patients with EC and 25 healthy controls using two different approaches: 1. a global proton nuclear magnetic resonance (NMR)-based approach, and, 2. a focused ultra high performance liquid chromatography (UHPLC)-based approach. Combined with orthogonal partial least-squares discriminant analysis (OPLS-DA), they could differentiate between EC patients and healthy subjects. The UHPLC-based focused approach proved to be superior in sensitivity and specificity. In the EC samples, the investigators identified nineteen significantly altered metabolites and significant perturbations to the following pathways: energy metabolism, tricarboxylic acid (TCA) cycle, ketogenesis, glycolysis, lipid metabolism, and amino acid metabolism. These findings could lead to the development of a screening tool for early stage EC.
|1 Apr 2014
Predicting Pre-Eclampsia: NMR Metabolomics
Marie Austdal - Researchers in Norway have found a useful set of biomarkers in urine and serum samples using NMR spectroscopy that are different between women who are not pregnant, those with normal pregnancies, and those with the debilitating and potentially life-threatening condition of pre-eclampsia.
Researchers in Norway have found a useful set of biomarkers in urine and serum samples using NMR spectroscopy that are different between women who are not pregnant, those with normal pregnancies, and those with the debilitating and potentially life-threatening condition of pre-eclampsia.
Marie Austdal, Ragnhild Bergene Skråstad, Astrid Solberg Gundersen, Rigmor Austgulen, Ann-Charlotte Iversen, Tone Frost Bathen of the Norwegian University of Science and Technology (NTNU), in Trondheim, Norway, have explored how NMR metabolomics might be used to study pre-eclampsia, for improved phenotyping and elucidating potential clues to the condition's aetiology and pathogenesis.
Pre-eclampsia is characterized by high blood pressure, hypertension, and a high concentration of protein in the urine of some pregnant women, there is often associated damage to the liver, kidneys and maternal endothelium. It can give rise to intrauterine growth restriction and if left untreated may develop into eclampsia, which are life-threatening seizures during pregnancy. It is one of the more common complications of pregnancy although the cause is yet to be elucidated definitively and there is no cure. That said, early delivery of the baby and placenta usually dispels the symptoms, but that brings with it the associated problems of premature birth.
By definition, the condition arises after the 20th week of pregnancy, most often close to full term but in some cases the syndrome appears very early, and these are the most life-threatening to both mother and baby. It has been linked to inadequate development of the placenta during the first trimester of pregnancy thought to be caused by an inappropriate immune response. However, some cases develop after the delivery of the baby. Antihypertensive medication is usually prescribed to bring the blood pressure into a healthy range and preclude the development of seizures. However, intravenous magnesium sulfate is sometimes used and steroids are administered to promote the development of the foetal lung. New insights into the cause and effects of the disease revealed by the NMR studies offer new hope for the future control of this condition.
The team explains that identifying biomarkers for pre-eclampsia could allow much more timely detection and so lead to healthier mothers and children. The collaboration is based at the Centre of Molecular Inflammation Research (CEMIR) and the MR Cancer Group at the Norwegian University of Science and Technology (NTNU) and details are reported in the journal Plos One.
"We have found that the metabolism in women who experience pre-eclampsia is clearly different from women with normal pregnancies," explains team member and NTNU graduate student Marie Austdal. "The differences suggest that pre-eclampsia has a similar profile to cardiovascular disease, and the inflammatory processes are reflected in the blood and urine of affected women. This abnormal metabolism may be present earlier, so that the disease may be predicted before onset." The biomarkers identified by the team correlate with metabolic issues in women as the condition develops during pregnancy. They were able to show a clear and significant difference in metabolomic profile between women from all three groups. Specifically, these differences could be linked to an increase in very low density lipoprotein (VLDL) fats and cholesterol for the pre-eclamptic women, and also reflect an increased stress response and inflammation in pre-eclampsia.
It is presumed that metabolic changes occur earlier than the manifestation of hypertension and proteinuria, which are the standard diagnostic symptoms. If it were possible to detect the onset of pre-eclampsia before it does any damage or its progress becomes entrenched, then it might be possible to intervene medically and prevent some women from developing the disease in the first place. The next step will simply be to use NMR to analyse samples taken from women in the earliest stages of pregnancy.
"The next step in this research is to analyse samples taken much earlier in pregnancy, around gestational week 12," Austdal told SpectroscopyNow. "Metabolomic profiling with NMR at this early stage may help identify women at risk of developing pre-eclampsia, so that they may be followed up more closely by their doctor during pregnancy. This research may also give clues to how and why the disease develops, an area in which many questions still remain."
|6 Mar 2014
Matej Orešič Appointed Principal Investigator of Systems Medicine at the Steno Diabetes Center
Press release from John Nolan, CEO of the Stenos Diabetes Center
Steno Diabetes Center is a world leading institution within diabetes care and prevention. Steno is owned by Novo Nordisk A/S and is a 'not for profit' organisation working in partnership with the Danish healthcare system. Steno treats around 5600 people with diabetes.
I am very pleased to announce that Professor Matej Orešič has been appointed to a new position as Principal Investigator, Systems Medicine, at the Steno Diabetes Center. Matej is a native of Slovenia, and during his impressive career to date he has made a significant contribution to the emerging fields of metabolomics, bioinformatics and systems biology – both nationally and internationally. His track record as a leader in these fields clearly demonstrates his ability to innovate and translate from basic laboratory science to a range of clinical fields including both type 1 and type 2 diabetes.
After graduating in Physics from the University of Ljubljana, Slovenia, he completed his PhD in Biophysics at Cornell University. Prior to moving to Finland, Prof. Orešič was a head of computational biology and modeling at Waltham/Massachusetts-based BG Medicine, Inc. and bioinformatician at LION Bioscience Research in Cambridge/MA. Since 2003 he has led research in domains of quantitative biology and bioinformatics at VTT Technical Research Centre of Finland (Espoo, Finland), where he is a Research Professor in Systems Biology and Bioinformatics. He is the Director of the Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research. His main research areas are metabolomics applications in biomedical research and integrative bioinformatics. He is particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities. Recent investigations include studies of longitudinal metabolic profiles of children who progressed to type 1 diabetes and studies of metabolic profiles in type 2 diabetes, non-alcoholic fatty liver disease, Alzheimer’s disease and psychotic disorders.
Matej Orešič is now an established international expert in the field of human metabolism. He has authored 180 peer reviewed papers, in addition to several reviews and a recent textbook “A Systems Biology Approach to Study Metabolic Syndrome”.
He is Principal Investigator on 8 current major programme grants, and was the only European scientist to be awarded a grant from the GE NFL Head Health Challenge programme in January 2014. Matej is a well-known and respected scientist in the Danish research community, with active and forthcoming collaborations both at Copenhagen University and the Novo Nordisk Center for Biosustainability at DTU.
Matej Orešič will take up his new position on April 1, 2014. I know that he is eager to move to Denmark and work with his new colleagues at Steno as well as to establish new collaborations in the Danish research community and abroad.
|5 Mar 2014
Metabolon Enters Into Collaboration Agreement with Human Longevity Inc. to Provide Metabolomic Profiling Services
HLI cofounders are J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D. and Peter H. Diamandis, M.D. Dr. Venter, who is well known for leading Celera to the successful sequencing of the human genome, has been a member of Metabolon’s Scientific Advisory Board since 2003.
Under the agreement Metabolon will apply its leading metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon’s metabolomic approach identifies the full complement of metabolites present in a human biological specimen. Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual’s health status, and provide markers and pathways associated with disease and drug action. In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
Commenting on the agreement Dr. Venter said, “The establishment of HLI is the next step beyond the sequencing of the human genome, and may at last provide useful clinical information for the treatment of disease that was lacking from genome mapping alone. Metabolon is a visionary and leader in the field of metabolomics, and I have great confidence in the company’s technology and ability to add significant value to HLI. Because of my position as a member of Metabolon’s Scientific Advisory Board, I have a deep personal appreciation of the company’s impressive methods and scientific expertise.”
John Ryals, Ph.D., Metabolon’s chief executive officer, said, “We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company. It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”
Source: Metabolon Press Release
|7-11 Apr 2014
Workshop Metabolomics 2014
|10 Apr 2014
Vamsi K. Mootha, MD
(Harvard Medical School), Steven
(Weill Cornell Medical College), Jennifer
(The New York Academy of Sciences)
Description: Mitochondria are the cell's "power plants" and serve a critical role in global metabolism. Accordingly, dysfunction or damage of mitochondria can greatly perturb metabolism, and underlies a diverse range of human diseases, ranging from neurodegenerative conditions (ALS, Alzheimer's and Parkinson's diseases), epilepsy, psychiatric illness and autism, to atherosclerotic heart disease, stroke, liver disease, type 2 diabetes and cancer.
For more details, please visit www.nyas.org/MitochondrialDisease
|28-29 Apr 2014
From Biomarker Identification to Market Entry
This 2-day conference will provide a neutral forum for international scientists and clinicians from academia, industry, and government — as well as healthcare policy makers, regulatory experts, insurance sector representatives, and other stakeholders — to discuss research, financial, and regulatory strategies that will facilitate CDx development and integration into clinical care. Presentations will illustrate successes and failures based on case studies; evaluate emerging applications of technologies such as epigenetics, bioinformatics, and nanotechnology; analyze diverse therapeutic target areas including the pioneering field of cancer along with inflammatory, infectious, cardiovascular, metabolic, and neurodegenerative diseases; recognize regulatory hurdles; and formulate solutions to better improve public health with CDx and personalized medicine.
For more information, please visit http://www.nyas.org/CDx2014
|30 Apr 2014
Analytical Tools for
Cutting-edge Metabolomics - a joint meeting of
the Analytical Division of the RSC and the
international Metabolomics Society
Analytical chemistry has been one of the driving forces behind the development of metabolomics research over the past decade. The conference will bring together exceptional scientists for a program consisting of plenary and invited talks, posters, as well as an oral session devoted to early career researchers. It will be an excellent opportunity for analytical chemists to learn more about metabolomics and its application, and for metabolomics scientists to improve their knowledge of cutting-edge bioanalytical tools.
Deadline for submission of abstracts: 14 March 2014
Prof. Jeremy Nicholson, Imperial College, London UK - Plenary speaker
Dr Julian Griffin, MRC Human Nutrition Research, Cambridge, UK
Prof. Roy Goodacre, University of Manchester, UK
Prof. Jean-Luc Wolfender, University of Geneva, Switzerland
Dr Steffen Neumann, Leibniz Institute of Plant Biochemistry, IPB Halle, Germany
Prof Paul Thomas, Loughborough University
|19-21 May 2014
8e Journées Scientifiques
du Réseau Français de Métabolomique et
The Amiens RFMF Congress (7 JS RFMF) took place in 2013 due to the generous support of Picardie Jules Verne University and various corporations. This event featured three keynote speakers, Age Smilde, Amsterdam, The Netherlands; Joachim Kopka, Golm-Postdam, Germany and Reza Salek, Cambridge, UK presenting state-of-the-art topics for metabolomics. This event was very successful, with 162 attendees from 75 public and private laboratories, 59 high-quality scientific presentations, 4 workshops and 6 industrial seminars. Four conferences, one workshop and one industrial seminar were held in English. The 2013 event gave an opportunity to gauge the strength and dynamic qualities of the French or French-speaking metabolomics and fluxomics community.
The 8th RFMF Congress will take place in Lyon (Eastern France) in May 19-21, 2014. The Metabolomic Community of the Lyon and Rhône-Alpes Region laboratories is the local organizer of the 2014 edition.
The key topics, chosen by Lyon metabolomics community, for the 8th RFMF Congress are:
The 8th RFMF Congress will include several workshops, one of them dealing with the Galaxy platform (workflow for metabolomics), one dealing with “Sample preparation for metabolomics study”, and a third one with “MetaboLights and COSMOS initiative”.
RFMF is generously supporting the attendance of students or post-docs (under 35 years old) at The 8th RFMF Congress Lyon 2014 through the provision of travel grants (up to €1000 for overseas applicants).
For more information on the 8th RFMF Congress, please visit https://colloque.inra.fr/8_js_rfmf_lyon_2014
|22-23 May 2014
Metabolomics Conference -
Advances & Applications in Human Disease
Special offer for Metabolomics Society Members and MetaboNews Subscribers:
Receive 30% off Registration with discount Code: meta30
For more information, see the event flyer or visit http://www.gtcbio.com/conference/metabolomics-overview
|16-17 Jun 2014
Informatics and Statistics
for Metabolomics (2014)
A poster announcing this workshop can be found here.
The workshop will cover many topics ranging from understanding metabolomics technologies, data collection and analysis, using pathway databases, performing pathway analysis, conducting univariate and multivariate statistics, working with metabolomic databases and exploring chemical databases. Participants will be given various data sets and short assignments to assist with the learning process.
This course is intended for graduate students, post-doctoral fellows, clinical fellows and investigators who are interested in learning about both bioinformatic and cheminformatic tools to analyze and interpret metabolomics data.
Prerequisite: Your own laptop computer. Minimum requirements: 1024x768 screen resolution, 1.5GHz CPU, 1GB RAM, recent versions of Windows, Mac OS X or Linux (Most computers purchased in the past 3-4 years likely meet these requirements). If you do not access to a laptop, you may loan one from the CBW. Please contact email@example.com for more information.
Pre-Readings: You are expected to have completed the following tutorials in R beforehand. The tutorial should be very accessible even if you have never used R before. Please complete the following: R Tutorial
Informatics and Statistics for Metabolomics Workshop flyer: http://www.metabonews.ca/Apr2014/events/CBW/metabolomics-cbw-2014.pdf
Canadian Bioinformatics Workshop Series flyer: http://www.metabonews.ca/Apr2014/events/CBW/flyer-cbw-2014_sm.pdf
|23-26 Jun 2014
Metabolomics 2014: 10th
Annual International Conference of the
We are delighted to host the 10th Anniversary of the International Conference of the Metabolomics Society (Metabolomics2014) at Keio University in Tsuruoka City, where the very first meeting of the society was held in 2005. Since then, Tsuruoka has grown to “a city of metabolomics”; various additional research buildings have been built, and two spin-out companies established. Tsuruoka is a pretty city located 500 km north of Tokyo (about 1 hour flight), and surrounded by beautiful Japanese nature, historic spots, and exotic culture. You will also enjoy the best authentic Japanese food and sake (rice wine), as well as hot springs. So, come celebrate the 10th anniversary of the society, and enjoy high-quality scientific presentations by top-notch researchers around the world.
|10-12 Sep 2014
Call for Papers
If you would like to be considered for an oral presentation at this meeting, Submit an abstract for review now!
Oral Presentation Submission Deadline: 31 January 2014
Call for Posters
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 27 August 2014
Drug Discovery and Pharma
Human Health and Nutrition
Microbial, Invertebrate and Environmental Applications
Data Analysis and Integration with Systems Biology
For more details, please visit the conference website.
|14-18 Sep 2014
Research Meeting ICRM 2014
At this ICRM 2014 conference also time has been reserved for contributed lectures. We invite you to submit abstracts for oral contributions, as well as for the two poster sessions. Abstracts can be submitted through the conference website at www.icrm2014.org. Submission deadline is May 1st 2014. Note that only submissions from registered attendees are taken into the review process.
Email contact: firstname.lastname@example.org
For more details, please visit http://www.icrm2014.org/
|29-30 Oct 2014||
Clinical Applications of
As the analytical power of mass spec is realised, the range of applications using this technology continues to expand. Focus at this meeting will be given to both traditional & emerging uses of MS in the clinic. Hot topics to be covered include developments of MS in applications ranging from vitamin D detection to newborn blood spot analysis. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to build new relationships and optimise your workflow.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Food Analysis Congress, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=CAMS2014
|29-30 Oct 2014
Food Analysis Congress
Focus will be given to advances in both the analysis of natural food allergens and toxins, as well as contaminants introduced through processing and packaging. Points for discussion will also include the ongoing issue of food traceability and efforts to reduce food fraud. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Clinical Applications of Mass Spectrometry track, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=FAC2014
|3-4 Dec 2014
Australian Lipids Meeting
While the first meeting focused on lipidomics we have expanded the scope for the second meeting to cover all aspects of lipid research. Planned topics include:
|28 Jun to 2 Jul 2015
Metabolomics 2015: 11th
Annual International Conference of the
Stay abreast of the latest Metabolomics Society news via the Twitter feed on the front page of the website (http://www.metabolomicssociety.org). Also you can follow us on Twitter: Metabolomics Society @MetabolomicsSoc and Metabolomics journal @Metabolomics. And you can visit us on Facebook.
Please come back later for detailed information about Metabolomics 2015 by visiting http://metabolomics2015.org.
This is a resource for
advertising positions in metabolomics. If you have a job
you would like posted in this newsletter, please email
Ian Forsythe (email@example.com).
Job postings will be carried for a maximum of 4
issues (8 weeks) unless the position is filled prior to
|Postdoctoral Fellow in Metabolic Flux Analysis for Pediatric Cancer Research||University of Texas at Austin||Austin, United States||1-Apr-2014
|Researcher Metabolomics and Food Safety||Eurofins Analytics France||Nantes, France||19-Mar-2014
|Postdoctoral scholar in ‘Genomics and Metabolomics integration'||University of California - Davis||Davis, CA, United States||19-Mar-2014||15-Apr-2014
|Early Stage Research Position m/f is available to work on the project: Body fluids Metabolomics in CKD progression||Helmholtz Zentrum München - German Research Center for Environmental Health - Helmholtz Association||Munich, Germany||17-Mar-2014
|Director of Computational Biology||Dynamic Biomarker Company||24-Feb-2014
|PhD in Identifying metabolomic contributions to disease mechanisms in dwarfisms caused by extracellular matrix gene defects||University of Manchester||Manchester, UK||3-Feb-2014||1-May-2014
||University of Manchester|
Ian J. Forsythe, M.Sc.MetaboNews
Department of Computing Science
University of Alberta
221 Athabasca Hall
Edmonton, AB, T6G 2E8, Canada
This newsletter is published in partnership between The Metabolomics Innovation Centre (TMIC, http://www.metabolomicscentre.ca/) and the Metabolomics Society (http://www.metabolomicssociety.org) for the benefit of the worldwide metabolomics community.
A single source destination for fee-for-service metabolic profiling including comprehensive metabolite identification, quantification, and analysis